Gendrot M et al., 2021-07-06: In vitro study of methylene blue alone and combined against two clinical SARS-CoV-2 isolates: MB acted at both entry and post-entry stages, was additive with quinine/mefloquine/pyronaridine, and ANTAGONISTIC with chloroquine, hydroxychloroquine and remdesivir , a finding that cuts against common combination protocols.
The combinations of methylene blue with chloroquine, hydroxychloroquine, desethylamodiaquine, piperaquine, lumefantrine, ferroquine, dihydroartemisinin and remdesivir were antagonist.
Abstract
Gendrot M et al., 2021-07-06: In vitro study of methylene blue alone and combined against two clinical SARS-CoV-2 isolates: MB acted at both entry and post-entry stages, was additive with quinine/mefloquine/pyronaridine, and ANTAGONISTIC with chloroquine, hydroxychloroquine and remdesivir , a finding that cuts against common combination protocols. Study type: in vitro (Vero E6, two clinical isolates IHUMI-3 and IHUMI-6, 48 h, RT-PCR); no light, no animals. Country: France (IHU Mediterranee Infection). EC50 0.41/1.85 uM (IHUMI-3) and 1.06/5.68 uM (IHUMI-6). Funding: French 'Investissement d'avenir' ANR-10-IAHU-03 and COVID-19 IHU Mediterranee Infection. Conflicts (declared): 'The authors declare no conflict of interest. The funders or Provepharm had no role in the design of the study…' , Provepharm (Marseille) makes methylene blue (Proveblue), so the maker is named in the disclosure. Also filed as MTP-56 (claims C10, C3). Study type: lab.
